Value of CSF β-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment

H. Hampel, S. J. Teipel, T. Fuchsberger, N. Andreasen, J. Wiltfang, M. Otto, Y. Shen, R. Dodel, Yansheng Du, Martin Farlow, H. J. Möller, K. Blennow, K. Buerger

Research output: Contribution to journalArticle

236 Citations (Scopus)

Abstract

Subjects with mild cognitive impairment (MCI) are at a high risk of developing clinical Alzheimer's disease (AD). We asked to what extent the core biomarker candidates cerebro-spinal fluid (CSF) β-amyloid1-42 (Aβ1-42) and CSF tau protein concentrations predict conversion from MCI to AD. We studied 52 patients with MCI, 93 AD patients, and 10 healthy controls (HC). The MCI group was composed of 29 patients who had converted to AD during follow-up, and of 23 patients who showed no cognitive decline. CSF Aβ1-42 and tau protein levels were assessed at baseline in all subjects, using enzyme-linked immunosorbent assays. For assessment of sensitivity and specificity, we used independently established reference values for CSF Aβ1-42 and CSF tau. The levels of CSF tau were increased, whereas levels of Aβ1-42 were decreased in MCI subjects. Aβ1-42 predicted AD in converted MCI with a sensitivity of 59% and a specificity of 100% compared to HC. Tau yielded a greater sensitivity of 83% and a specificity of 90%. In a multiple Cox regression analysis within the MCI group, low baseline levels of Aβ1-42, but not other predictor variables (tau protein, gender, age, apolipoprotein E ε4 carrier status, Mini Mental Status Examination score, observation time, antidementia therapy), correlated with conversion status (P < 0.05). Our findings support the notion that CSF tau and Aβ1-42 may be useful biomarkers in the early identification of AD in MCI subjects.

Original languageEnglish
Pages (from-to)705-710
Number of pages6
JournalMolecular Psychiatry
Volume9
Issue number7
StatePublished - Jul 2004

Fingerprint

Cerebrospinal Fluid
Alzheimer Disease
tau Proteins
Biomarkers
Apolipoprotein E4
Cognitive Dysfunction
Reference Values
Enzyme-Linked Immunosorbent Assay
Regression Analysis
Observation
Sensitivity and Specificity

Keywords

  • Alzheimer's disease (AD)
  • Beta-amyloid
  • Biomarker
  • Cerebro-spinal fluid (CSF)
  • Conversion
  • Early diagnosis
  • Mild cognitive impairment (MCI)
  • Prediction
  • Prognosis
  • Tau

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health

Cite this

Hampel, H., Teipel, S. J., Fuchsberger, T., Andreasen, N., Wiltfang, J., Otto, M., ... Buerger, K. (2004). Value of CSF β-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Molecular Psychiatry, 9(7), 705-710.

Value of CSF β-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. / Hampel, H.; Teipel, S. J.; Fuchsberger, T.; Andreasen, N.; Wiltfang, J.; Otto, M.; Shen, Y.; Dodel, R.; Du, Yansheng; Farlow, Martin; Möller, H. J.; Blennow, K.; Buerger, K.

In: Molecular Psychiatry, Vol. 9, No. 7, 07.2004, p. 705-710.

Research output: Contribution to journalArticle

Hampel, H, Teipel, SJ, Fuchsberger, T, Andreasen, N, Wiltfang, J, Otto, M, Shen, Y, Dodel, R, Du, Y, Farlow, M, Möller, HJ, Blennow, K & Buerger, K 2004, 'Value of CSF β-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment', Molecular Psychiatry, vol. 9, no. 7, pp. 705-710.
Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M et al. Value of CSF β-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Molecular Psychiatry. 2004 Jul;9(7):705-710.
Hampel, H. ; Teipel, S. J. ; Fuchsberger, T. ; Andreasen, N. ; Wiltfang, J. ; Otto, M. ; Shen, Y. ; Dodel, R. ; Du, Yansheng ; Farlow, Martin ; Möller, H. J. ; Blennow, K. ; Buerger, K. / Value of CSF β-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. In: Molecular Psychiatry. 2004 ; Vol. 9, No. 7. pp. 705-710.
@article{5dc7b0f7e7c74c2fba7dd080c652525f,
title = "Value of CSF β-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment",
abstract = "Subjects with mild cognitive impairment (MCI) are at a high risk of developing clinical Alzheimer's disease (AD). We asked to what extent the core biomarker candidates cerebro-spinal fluid (CSF) β-amyloid1-42 (Aβ1-42) and CSF tau protein concentrations predict conversion from MCI to AD. We studied 52 patients with MCI, 93 AD patients, and 10 healthy controls (HC). The MCI group was composed of 29 patients who had converted to AD during follow-up, and of 23 patients who showed no cognitive decline. CSF Aβ1-42 and tau protein levels were assessed at baseline in all subjects, using enzyme-linked immunosorbent assays. For assessment of sensitivity and specificity, we used independently established reference values for CSF Aβ1-42 and CSF tau. The levels of CSF tau were increased, whereas levels of Aβ1-42 were decreased in MCI subjects. Aβ1-42 predicted AD in converted MCI with a sensitivity of 59{\%} and a specificity of 100{\%} compared to HC. Tau yielded a greater sensitivity of 83{\%} and a specificity of 90{\%}. In a multiple Cox regression analysis within the MCI group, low baseline levels of Aβ1-42, but not other predictor variables (tau protein, gender, age, apolipoprotein E ε4 carrier status, Mini Mental Status Examination score, observation time, antidementia therapy), correlated with conversion status (P < 0.05). Our findings support the notion that CSF tau and Aβ1-42 may be useful biomarkers in the early identification of AD in MCI subjects.",
keywords = "Alzheimer's disease (AD), Beta-amyloid, Biomarker, Cerebro-spinal fluid (CSF), Conversion, Early diagnosis, Mild cognitive impairment (MCI), Prediction, Prognosis, Tau",
author = "H. Hampel and Teipel, {S. J.} and T. Fuchsberger and N. Andreasen and J. Wiltfang and M. Otto and Y. Shen and R. Dodel and Yansheng Du and Martin Farlow and M{\"o}ller, {H. J.} and K. Blennow and K. Buerger",
year = "2004",
month = "7",
language = "English",
volume = "9",
pages = "705--710",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Value of CSF β-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment

AU - Hampel, H.

AU - Teipel, S. J.

AU - Fuchsberger, T.

AU - Andreasen, N.

AU - Wiltfang, J.

AU - Otto, M.

AU - Shen, Y.

AU - Dodel, R.

AU - Du, Yansheng

AU - Farlow, Martin

AU - Möller, H. J.

AU - Blennow, K.

AU - Buerger, K.

PY - 2004/7

Y1 - 2004/7

N2 - Subjects with mild cognitive impairment (MCI) are at a high risk of developing clinical Alzheimer's disease (AD). We asked to what extent the core biomarker candidates cerebro-spinal fluid (CSF) β-amyloid1-42 (Aβ1-42) and CSF tau protein concentrations predict conversion from MCI to AD. We studied 52 patients with MCI, 93 AD patients, and 10 healthy controls (HC). The MCI group was composed of 29 patients who had converted to AD during follow-up, and of 23 patients who showed no cognitive decline. CSF Aβ1-42 and tau protein levels were assessed at baseline in all subjects, using enzyme-linked immunosorbent assays. For assessment of sensitivity and specificity, we used independently established reference values for CSF Aβ1-42 and CSF tau. The levels of CSF tau were increased, whereas levels of Aβ1-42 were decreased in MCI subjects. Aβ1-42 predicted AD in converted MCI with a sensitivity of 59% and a specificity of 100% compared to HC. Tau yielded a greater sensitivity of 83% and a specificity of 90%. In a multiple Cox regression analysis within the MCI group, low baseline levels of Aβ1-42, but not other predictor variables (tau protein, gender, age, apolipoprotein E ε4 carrier status, Mini Mental Status Examination score, observation time, antidementia therapy), correlated with conversion status (P < 0.05). Our findings support the notion that CSF tau and Aβ1-42 may be useful biomarkers in the early identification of AD in MCI subjects.

AB - Subjects with mild cognitive impairment (MCI) are at a high risk of developing clinical Alzheimer's disease (AD). We asked to what extent the core biomarker candidates cerebro-spinal fluid (CSF) β-amyloid1-42 (Aβ1-42) and CSF tau protein concentrations predict conversion from MCI to AD. We studied 52 patients with MCI, 93 AD patients, and 10 healthy controls (HC). The MCI group was composed of 29 patients who had converted to AD during follow-up, and of 23 patients who showed no cognitive decline. CSF Aβ1-42 and tau protein levels were assessed at baseline in all subjects, using enzyme-linked immunosorbent assays. For assessment of sensitivity and specificity, we used independently established reference values for CSF Aβ1-42 and CSF tau. The levels of CSF tau were increased, whereas levels of Aβ1-42 were decreased in MCI subjects. Aβ1-42 predicted AD in converted MCI with a sensitivity of 59% and a specificity of 100% compared to HC. Tau yielded a greater sensitivity of 83% and a specificity of 90%. In a multiple Cox regression analysis within the MCI group, low baseline levels of Aβ1-42, but not other predictor variables (tau protein, gender, age, apolipoprotein E ε4 carrier status, Mini Mental Status Examination score, observation time, antidementia therapy), correlated with conversion status (P < 0.05). Our findings support the notion that CSF tau and Aβ1-42 may be useful biomarkers in the early identification of AD in MCI subjects.

KW - Alzheimer's disease (AD)

KW - Beta-amyloid

KW - Biomarker

KW - Cerebro-spinal fluid (CSF)

KW - Conversion

KW - Early diagnosis

KW - Mild cognitive impairment (MCI)

KW - Prediction

KW - Prognosis

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=3142743789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142743789&partnerID=8YFLogxK

M3 - Article

C2 - 14699432

AN - SCOPUS:3142743789

VL - 9

SP - 705

EP - 710

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 7

ER -